Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click ...

Stock investors have many options to choose among, of course. These include individual equities, exchange-traded funds (ETFs) ...

With $6 billion left in firepower, Pfizer is planning transactions in the hundreds of millions to the low-billions range, ...

San Diego–based Ventyx Biosciences has what pharma wants, according to William Blair: two NLRP3 inhibitors for inflammatory ...

Shares of Pfizer PFE dropped more than 3% on Tuesday after the company announced its financial outlook for the full year 2026 ...

Pfizer signaled Tuesday it expects a challenging 2026 as it invests in new products to offset declines in Covid-19 revenues ...

Large deals in H2 2025 included Novartis’ $12 billion acquisition of Avidity Biosciences and Genmab’s buyout of Merus, ...

Pfizer Inc. forecast little to no sales growth next year as the drugmaker undertakes an effort to refresh its pipeline of hit ...

(Reuters) -Shares of Metsera fell over 15% in early trading on Monday, after the weight-loss drug developer accepted a sweetened offer from Pfizer to end a fierce bidding war between the pharma giant ...

Pfizer's agreement to buy Metsera just adds to the 83 healthcare deals counted by Goldman Sachs that were above $100 million in value and announced this year. M&A, however, has not been enough for ...

In this week’s edition of InnovationRx, we look at French healthtech Doctolib’s potential large secondary round, Alice ...